Breakthrough Victoria shells out $12 million for peanut allergy treatment developer Aravax

The Victorian government-funded Breakthrough Victoria has made a $12 million investment into Aravax, part of a $66 million funding round in the biotechnology company, which is developing a novel peanut allergy treatment. Aravax is a clinical-stage company developing PVX108, its immunotherapy product that uses synthetic peptides to mimic key parts of peanut proteins to retrain…

Breakthrough Victoria invests in gut gas detection startup

Breakthrough Victoria has announced an investment in Atmo Biosciences, a medical technology company that has developed capsules that are swallowed and electronically diagnose gastrointestinal disorders. Breakthrough Victoria — an independent company set up in 2021 to manage the state government’s $2 billion Breakthrough Victoria Fund — did not disclose the size of the investment. In…

State government announces funding for commercialising university research

The Victorian government has announced new co-investment partnerships with five Victorian universities, with $87 million in total to be allocated through the Breakthrough Victoria – University Innovation Platform program  The new partnerships are with Deakin University, La Trobe University, Monash University, RMIT University and Swinburne University, and according to industry minister Ben Carroll “will help…